BHV-3100 / Nxera Pharma, Pfizer - LARVOL DELTA

A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562 (clinicaltrials.gov) - P1 | N=33 | Terminated | Sponsor: Heptares Therapeutics Limited | N=88 ➔ 33 | Trial completion date: Aug 2022 ➔ Nov 2021 | Not yet recruiting ➔ Terminated | Trial primary completion date: Aug 2022 ➔ Nov 2021; Early termination of study pending evaluation of emerging preclinical profile.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

A Phase 1 Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562 (clinicaltrials.gov) - P1; N=88; Not yet recruiting; Sponsor: Heptares Therapeutics Limited

Clinical • New P1 trial

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven (PRNewswire) - "Sosei Group Corporation...today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study...The trial is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose and multiple ascending doses of subcutaneous HTL0022562 in healthy adult subjects. The trial aims to enroll 88 subjects at a single center in the UK and is expected to complete in 2022."

Enrollment status • Trial status • CNS Disorders • Migraine • Pain